I’ve been seeing a lot of speculation about a buyout for SLS if things go well, but there is a critical detail in the capital structure that everyone seems to be overlooking. After digging through the 424B5 filings and the specific warrant agreements, I found a clause regarding "Fundamental Transactions" that effectively acts as a poison pill. Specifically, the text states that in the event of a merger or buyout, warrant holders have the right to demand the company purchase their warrants for cash at their "Black-Scholes Value" rather than just their intrinsic value.
This is a nightmare for any potential acquirer because the Black-Scholes model values options based heavily on historical volatility and time remaining until expiration. Since SLS is an extremely volatile biotech stock and these warrants have fresh five-year terms from the recent inducement, the formula can output a value significantly higher than the actual buyout price. For example, even if a pharma company offers $10 per share, the Black-Scholes value of the warrants could be calculated at $15 or more due to the volatility premium. This forces the acquirer to pay a massive "warrant tax" in cold hard cash to hedge funds, effectively destroying the ROI of the deal.
It seems likely that the "smart money" funds like Anson are holding these positions not just because they believe in the drug, but because this contractual clause guarantees them a payout leverage that creates a massive hurdle for any standard acquisition. Unless the warrant holders agree to a negotiated haircut, this structure suggests SLS might be forced to commercialize alone rather than being bought out, simply because the math doesn't work for a buyer. Has anyone seen a biotech get acquired with this specific Black-Scholes overhang intact, or does this essentially kill the M&A thesis?